3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
5
Polycystic Ovary Syndrome
2
Obesity
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Triple Negative Breast Neoplasms
1
Tracheal Diseases
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Salivary Gland Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Overweight
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Motor Activity
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Lymphoma
1
Lung Neoplasms
1
Localized Prostate Cancer
1
Leukemia
1
Leiomyosarcoma
1
Interventions
Cyclophosphamide
28
fludarabine
19
Rituximab
17
obinutuzumab
12
venetoclax
10
Lenalidomide
9
Bendamustine Hydrochloride
9
Prednisone
7
zanubrutinib
6
Doxorubicin
6
Blood Specimen Collection
6
pembrolizumab
5
ibrutinib
5
fludarabine phosphate
5
Biopsy
5
glofitamab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Exercise
4
loncastuximab tesirine
3
gamma-Globulins
3
axicabtagene ciloleucel
3
acalabrutinib
3
Temozolomide
3
Surveys and Questionnaires
3
Palliative Care
3
Mycophenolic Acid
3
Methotrexate
3
Mesna
3
Magnetic Resonance Spectroscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma
×
Tablets
×
Clear all
NCT06643221
2024-10-16
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
100 enrolled